Recombinant tissue plasminogen activator (tPA) is the only effective fibrinolytic treatment at the acute stage of ischemic stroke; however, it is associated with an increased risk of brain edema and secondary hemorrhagic transformation. The gene discussed is PLAT; the disease is ischemic stroke.